The FDA has granted clearance for GE Healthcare’s newest PET/CT scanner, which will be added to GE’s Discovery product line.
The new system will be optimized for use in oncology, according to GE. The system will use high-sensitivity crystals, along with GE’s VUE Point HD imaging to help clinicians advance towards the goal of motion free PET/CT imaging, the company said.
VUE Point HD can help improve the ability to detect lesions, treatment planning and quantitative accuracy, improved contrast-to-noise of moving lesions up to 60 percent versus static acquisition, GE said.
The company anticipates shipping the first new scanners to customers in the fourth quarter of this year, according to Henry Hummel general manager of the PET/CT business at GE Healthcare.